Review questions

1. In the published literature, what are the reported frequencies of MTAP deletions among adult patients aged ≥18 years with cholangiocarcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gallbladder carcinoma, glioblastoma, non-squamous cell lung cancer, mesothelioma, diffuse large B-cell lymphoma (DLBCL), or acute lymphoblastic leukemia (ALL) and among pediatric patients aged <18 years with ALL?
2. In the published literature, what are the reported MTAP laboratory testing frequencies and types (protein expressions and genomic testing including next-generation sequencing [NGS]) among adult patients aged ≥18 years with cholangiocarcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gallbladder carcinoma, glioblastoma, non-squamous cell lung cancer, mesothelioma, DLBCL, or ALL and among pediatric patients aged <18 years with ALL?
3. In the published literature, what are the reported prognostic values such as survival and response (e.g., overall survival [OS], progression-free survival [PFS], objective response rate [ORR], resection rate [RR]) associated with MTAP deletions among adult patients aged ≥18 years with cholangiocarcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gallbladder carcinoma, glioblastoma, non-squamous cell lung cancer, mesothelioma, DLBCL, or ALL and among pediatric patients aged <18 years with ALL?
4. In the published literature, what are the reported associations between MTAP deletions and clinical, molecular, and sociodemographic factors among adult patients aged ≥18 years with cholangiocarcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gallbladder carcinoma, glioblastoma, non-squamous cell lung cancer, mesothelioma, DLBCL, or ALL and among pediatric patients aged <18 years with ALL?